Skip to main content
Premium Trial:

Request an Annual Quote

Betty Woods, David Rutledge, Jay Johnston, Gerard Vaillant, and Mark Allen


Beckman Coulter has named Betty Woods non-executive chairman, the company said last week.

Woods, who is an 11-year veteran of the Beckman Coulter board, will succeed retiring executive chairman John Wareham. Woods is former president and CEO of Premera Blue Cross, and CEO of Premera, its holding company. She has been a member of the Beckman Coulter board since 1994. She is currently chair of the organization and compensation committee, Beckman said.

David Rutledge has been named chief financial officer at Southern Research Institute.

Rutledge has been with SRI for 19 years, serving as the company’s controller for the last seven years, SRI said. He joined SRI in 1986 as a contracts specialist.

Luminex said last week that its board of directors has appointed Jay Johnston and Gerard Vaillant to the board to serve as Class II and Class I directors, respectively. In addition, Luminex said that current board members Laurence Hirsch and Thomas Caskey will retire from the board.

Johnston currently serves as chairman of QuesTek Innovations. From 1975 to 1999, he held various positions at Abbott Laboratories, most recently as corporate vice president for diagnostic assays and systems. He holds an MBA in general management from Amos Tuck School of Business Administration.

Vaillant held a number of positions with Johnson & Johnson from 1981 to 2004, Luminex said. He has also served as chairman for Ortho-Clinical Diagnostics, Veridex, and Therakos. He currently serves on the board of directors for Sensors for Medicine and Science and Tecan.

Mark Allen has been promoted to senior vice president and managing director of Tripos Discovery Research, a UK-based unit of Tripos, the St. Louis-based company said last week. He used to be vice president of operations. Allen succeeds Peter Hecht, who is leaving Tripos to become CEO of Oridis Biomed. Hecht will remain a scientific advisor to the company.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.